Business Wire

VA-DXC-TECHNOLOGY

25.2.2020 15:02:10 CET | Business Wire | Press release

Share
DXC Technology Advances Deployments of Augmented, Virtual and Mixed Reality Technologies for Enterprises in the Connected, Digital Workplace

DXC Technology (NYSE: DXC) today highlighted how it is helping enterprises accelerate the adoption of augmented reality (AR), virtual reality (VR) and mixed reality (MR) technologies to support immersive experiences in ways that can significantly improve productivity, quality and efficiency.

According to Gartner, by 2022, 70% of enterprises will be experimenting with immersive technologies for consumer and enterprise use, and 25% will have deployed them to production.* DXC is using AR, VR and MR technologies today to transform the future of work, and the company is seeing widespread implementation to improve safety, connect remote workers, assist with complex tasks and enhance training and collaboration – all in ways that drive business results and profitability.

“Digital transformation in the workplace is edging towards an inflection point as enterprises are incorporating immersive solutions that connect the real world with the virtual world,” said Maria Pardee, DXC’s senior vice president and general manager, Workplace and Mobility. “DXC is using the power of AR, VR and MR to align the next-generation digital capabilities employees want so they can be more mobile and independent, with the critical security, production prowess and agility that today’s businesses demand.”

DXC Deploys Mixed Reality Employee Training at Water Treatment Leader Ixom

A market leader in water treatment and chemical distribution in Australia and New Zealand, Ixom turned to DXC to develop a custom training and assessment application using mixed reality on Microsoft HoloLens.

In the past, Ixom training and learning assessments were conducted at customer sites, requiring travel, scheduling and employee resources to mitigate safety risks. Now, using DXC’s mixed reality application for Microsoft HoloLens — custom built for Ixom — employees can participate in the required training and learning assessment at any Ixom office or remote location. The resulting increase in flexibility, autonomy and mobility has reduced Ixom travel costs, minimized employee safety risks and essentially eliminated the potential for exposure to hazardous materials during training at treatment facilities.

DXC is named a Leader in Advanced Digital Workplace Services Overall in the NelsonHall Evaluation & Assessment Tool (NEAT) Report 2019 . DXC is also an official partner in the Microsoft HoloLens Mixed Reality Partner Program, a status that reflects the company’s commitment to designing, developing and deploying solutions that help customers accelerate their digital transformations using mixed reality technologies.

The following DXC offerings enable immersive solutions using AR/VR technologies:

  • DXC AR/VR services consist of AR/VR consulting, custom application development and system integration for a range of AR/VR devices including Microsoft HoloLens. DXC is also a Distributor Managed Partner for HoloLens 2 and provides services for MR business applications such as Microsoft Dynamics 365 Guides.
  • DXC Remote Expert is an innovative AR solution that enables field workers in various industries (automotive, energy and utilities, manufacturing, travel and transportation, and healthcare) to display work instructions via a hands-free interface on their wearable or mobile devices and connect to experts at other locations when they need guidance.
  • DXC Unified Endpoint Management enables enterprises to manage and secure mobile, PC, internet-of-things (IoT) and wearable devices in a single pane of glass. DXC’s collaboration with industry-leading technology partners, combined with DXC transformation, delivery and support services, provides users with secure and seamless access to enterprise applications, data and services independent of operating system, device type or location.
  • DXC Workplace IoT enables enterprises to securely deploy and manage smart connected devices by combining IoT solutions, best practices, and market-leading platforms and technology partners to improve production, operational and human outcomes; automate processes with analytics; and gain situational awareness.
  • DXC Open Health Connect creates a connected ecosystem that optimizes services for patients, healthcare providers and payers, using AR to provide better patient outcomes.

*Smarter With Gartner, Top 10 Strategic Technology Trends for 2019, October 2019, https://www.gartner.com/smarterwithgartner/gartner-top-10-strategic-technology-trends-for-2019 .

About DXC Technology

DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy our enterprise technology stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.technology .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release

Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d

Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release

A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release

New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release

Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer

Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release

Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye